EMERALD Study – Relutrigine for seizures in DEE’s
The GLUT1 Deficiency Foundation is sharing information about a new clinical trial for Relutrigine to understand how safe and effective it is in reducing seizures in individuals who have epilepsy caused by genetic syndromes.
All people with GLUT1 Deficiency may not be eligible, but the G1DF wants to make the community aware of this opportunity so individuals and their families can decide with their healthcare teams if this is right for them.
You can find more information below, and join the virtual meeting with PRAXIS and the GLUT1 community on Tuesday, August 26th to learn more and ask questions with the study team.
Praxis Precision Medicines is now enrolling for their EMERALD Study – open to individuals with Developmental and Epileptic Encephalopathies (DEE’s) caused by genetic epilepsies and syndromes like GLUT1 Deficiency.
The EMERALD Study will test a new treatment called Relutrigine. This medication is being studied as an add-on therapy to help reduce seizures.
Eligibility:
- Ages 2–65 in the United States, Europe, Australia, and South America
- Had 4 or more motor seizures in the past 4 weeks
- May currently use and remain on a ketogenic diet or other treatments
Participation Options:
- Remote, in-clinic, or hybrid enrollment
- Expanded access may be available after the trial
Principal Investigators: multiple
Anticipated Start Date: now enrolling
Sponsor: Praxis Precision Medicines
Meet with Praxis on Zoom:
Tuesday, August 26th at 11:00 AM Eastern
Praxis will host a meeting for the GLUT1 community where they’ll share more about the study, the mechanisms of action for Relutrigine, eligibility criteria for individuals with GLUT1 Deficiency, and answer questions.
meeting link
Meeting ID: 964 3453 3184
Passcode: 184081
More Resources:
information about countable motor seizures
EMERALD Study flyer
EMERALD Study website
